Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Brain stimulation relieves pain in fibromyalgia patients

31 Jul 2020

Extended treatment with transcranial direct current stimulation (tDCS) applied over dorsolateral prefrontal cortex (DLPFC) induces large reductions in pain in fibromyalgia patients, as shown in a study.

Twenty women (average age, 49 years) with fibromyalgia were randomized to undergo 60 sessions of home-based anodal tDCS (n=10) or sham tDCS (n=10). During active treatment, 2-mA current was applied for 30 minutes for 5 consecutive days for 12 weeks. Treatment was self-administered with a specially developed device following in-person training.

Baseline characteristics were balanced between the treatment groups. In the guessing treatment assessment, 19 patients (95.1 percent) believed receiving brain tDCS and one patient (5 percent) believed to have received sham stimulation.

The cumulative incidence of burning, tingling, itchiness, and redness in the active and sham treatment groups were 25 percent and 17 percent, respectively (p=0.165). On the other hand, the cumulative incidence of a headache, neck pain, mood swings, and concentration difficulties were 7 percent and 16 percent, respectively (p=0.046). All side effects were classified as mild.

After the first 20 sessions, active tDCS reduced cumulative pain scores by 45.65 percent relative to sham treatment (mean, 7.25 vs 3.94). After 60 sessions, pain scores further decreased by 62.06 percent in the active group (from 7.25 to 2.75) and by only 24.92 percent in the sham group (from 7.10 to 5.33).

Anodal tDCS also reduced the likelihood of requiring analgesics by 55 percent. Higher serum levels of the brain-derived neurotrophic factor predicted higher decreases on the pain scores across treatment.

The findings support the feasibility of home-based tDCS in the treatment of women with fibromyalgia, researchers said. They pointed out that brain-derived neurotrophic factor to index neuroplasticity may be a valuable predictor of the tDCS effect on pain scores decreases across treatment.

Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.